As Entresto Hits Japan Market, Novartis Poised to Tap All Channels to Push Global Blockbuster

Adriaan Kooy, Corporate Officer, Cardiovascular, Renal & Metabolism Business Franchise, Novartis Pharma Novartis’ global blockbuster Entresto (sacubitril valsartan sodium hydrate) made its long-awaited debut in Japan on August 26 upon its NHI price listing, becoming the first drug to offer...read more